ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

Firma DAIICHI SANKYO EUROPEMedizintechnik, , , , , , , , , , , , , ,

First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction in the risk of death versus chemotherapy Breakthrough Therapy Designation recently granted in the U.S. for ENHERTU in this setting Mehr

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

Firma DAIICHI SANKYO EUROPEMedizintechnik, , , , , , , , , , , , , ,

Results from the phase 2 DESTINY-CRC01  trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU®     (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines Mehr

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

Firma DAIICHI SANKYO EUROPEMedizintechnik, , , , , , , , , , , , , ,

9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently granted in the U.S. in this setting Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Mehr